Business Wire

Encoded Therapeutics to Present Initial ENVISION Natural History Study Data of Children With SCN1A+ Dravet Syndrome at the American Epilepsy Society 2021 Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics today announced the upcoming presentation of initial data from the ENVISION prospective natural history study of children with SCN1A+ ...
Business Wire

Encoded Therapeutics Presents Data Showing That Children With Dravet Syndrome Experience Early, Substantial Neurodevelopment Deficits and Seizure Burden, at the American ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics today announced initial findings from its ENVISION natural history study of children living with SCN1A+ Dravet syndrome, a rare ...
Morningstar

New Preclinical Data from Encoded Therapeutics Demonstrate Therapeutic Potential of its One-time, Non-opioid Gene Therapy Candidate for Chronic Pain

Preclinical data show the vectorized miRNA candidate achieved durable knockdown of SCN9A (NaV1.7), a genetically validated pain target historically difficult to modulate In non-human primates, ...
Morningstar

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS ...
PharmiWeb

Encoded Therapeutics Strengthens Clinical Leadership Team with Appointment of Professor Joseph Sullivan, M.D., as Vice President of Clinical Development

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#Dravetsyndrome--Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing genetic medicines for severe neurological ...
FierceBiotech

Encoded lays off 29% of staff to fund Dravet syndrome gene therapy trial

Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D toward its Dravet syndrome program. The asset in question, dubbed ...
FierceBiotech

GV-backed Encoded lays off 10% of staff nearly 3 years after $135M series D

Encoded Therapeutics is joining the ranks of biotechs pummeled by the whiplash of a difficult biotech market, laying off "close to 10%" of its team, according to Chief Business Officer David McNinch.
The Bakersfield Californian

Encoded Therapeutics Strengthens Clinical Leadership Team with Appointment of Professor Joseph Sullivan, M.D., as Vice President of Clinical Development

Encoded Therapeutics Inc. (“Encoded”), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced the appointment of Dr. Joseph Sullivan M.D ...
PharmiWeb

Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

– Clinically meaningful gains in multiple measures of neurodevelopment across initial three dose levels, including substantial improvements in cognitive skills by 16 weeks in participants dosed before ...